El interés en corto de Tempus AI da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de Tempus AI. Los datos de interés en corto se actualizan cada dos semanas.

Tempus AI (NASDAQ:TEM) Bolsa, Informe de interés en corto

Tempus AI

Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.

Cathie Wood Bets On Baidu As Chinese AI Buzz Intensifies, Ark Loads Up On $12.4 Million Worth Of Stock

Equities

News

Markets

ETFs

$BTC

AMZN

ARKF

ARKK

ARKQ

ARKW

COIN

NVDA

Ark Invest realiza millonarias compras en Amazon, Nvidia y Coinbase en medio de caídas bursátiles y nuevos aranceles.

Ark Invest compra acciones de Amazon pese a caída y lanza apuesta de 5,76 millones

Ark Invest's Cathie Wood Says Belief In Bitcoin's $1.5 Million Price Target By 2030 Has Grown

ARKG

GTLB

ILMN

IRDM

PATH

Ark Invest realizó movimientos estratégicos en el sector tecnológico, ajustando su portafolio con compras clave y ventas millonarias.

Cathie Wood apuesta por Tempus AI y AMD mientras reduce su posición en Meta

Cathie Wood's Wednesday Moves: Ark Pours $1.36 Million Into Tempus AI Shares Following Deep 6 AI Acquisition, Offloads Rocket Lab Stock

General

HOOD

El jueves, Ark Invest de Cathie Wood realizó importantes intercambios, centrándose en la adquisición de acciones de Robinhood Markets Inc (NASDAQ:HOOD), Coinbase Global Inc (NASDAQ:COIN

Ark Invest apuesta por Robinhood (HOOD), Coinbase (COIN) y Tempus AI (TEM)

Tempus AI Inc

TEMCO

J.P. Morgan Exchange-Traded Fund Trust JPMorgan Climate Change Solutions ETF

PERSOL HLDG CO LTD ORD by Persol Holdings Co Ltd

Persol Holdings Co Ltd

Touchstone ETF Trust Touchstone Sands Capital Emerging Markets ex-China Growth ETF

Alliance Global Partners analyst Gaurav Mehta initiates coverage on Sky Harbour Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SKYH#NYSE">SKYH</a>) with a Buy rating and announces Price Target of $14.5.

Price Target

Initiation

Analyst Ratings

SKYH

Alliance Global Partners Initiates Coverage On Sky Harbour Group with Buy Rating, Announces Price Target of $14.5

Citigroup analyst Leandro Bastos initiates coverage on CI&amp;T (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CINT#NYSE">CINT</a>) with a Buy rating and announces Price Target of $7.

CINT

Citigroup Initiates Coverage On CI&T with Buy Rating, Announces Price Target of $7

Citigroup analyst Filippo Falorni maintains Procter &amp; Gamble (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PG#NYSE">PG</a>) with a Buy and lowers the price target from $200 to $181.

Citigroup Maintains Buy on Procter & Gamble, Lowers Price Target to $181

HubSpot (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUBS#NYSE">HUBS</a>) has outperformed the market over the past 10 years by 21.51% on an annualized basis producing an average annual return of 31.61%. Currently, HubSpot has a market capitalization of $31.48 billion. 
Buying $100 In HUBS: If an investor had bought $100 of HUBS stock 10 years ago, it would be worth $1,527.60 today based on a price of $603.55 for HUBS at the time of writing.
<h3>HubSpot's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745590517_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

HUBS

$100 Invested In This Stock 10 Years Ago Would Be Worth This Much Today

HC Wainwright &amp; Co. analyst Joseph Pantginis maintains VYNE Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VYNE#NASDAQ">VYNE</a>) with a Buy and lowers the price target from $5.75 to $4.5.

VYNE

HC Wainwright & Co. Maintains Buy on VYNE Therapeutics, Lowers Price Target to $4.5

Citigroup analyst Filippo Falorni maintains PepsiCo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEP#NASDAQ">PEP</a>) with a Buy and lowers the price target from $170 to $160.

Citigroup Maintains Buy on PepsiCo, Lowers Price Target to $160

Benchmark analyst David Williams maintains Plexus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLXS#NASDAQ">PLXS</a>) with a Buy and lowers the price target from $170 to $160.

PLXS

Benchmark Maintains Buy on Plexus, Lowers Price Target to $160

Citigroup analyst Ygal Arounian maintains Ziff Davis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZD#NASDAQ">ZD</a>) with a Neutral and lowers the price target from $52 to $35.

Citigroup Maintains Neutral on Ziff Davis, Lowers Price Target to $35

U.S. stocks traded lower this morning, with the Dow Jones index falling around 200 points on Friday.
Following the market opening Friday, the Dow traded down 0.50% to 39,894.22 while the NASDAQ fell 0.11% to 17,147.08. The S&amp;P 500 also fell, dropping, 0.24% to 5,471.83.
Check This Out: <a href="https://www.benzinga.com/25/04/45006599/how-to-earn-500-a-month-from-dominos-pizza-stock-ahead-of-q1-earnings">How To Earn $500 A Month From Domino&#8217;s Pizza Stock Ahead Of Q1 Earnings</a>
Leading and Lagging Sectors Communication services shares jumped by 0.9% on Friday.
In trading on Friday, health care fell by 0.9%.
Top Headline
Alphabet Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) reported better-than-expected first-quarter financial results after the closing bell on Thursday.
Alphabet announced a 5% increase to the dividend with the quarterly payout going to 21 cents per share. The company also announced the Board of Directions authorized a $70 billion share repurchase plan on April 23.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Odyssey Marine Exploration, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMEX#NASDAQ">OMEX</a>) shares shot up 80% to $1.53. U.S. President Donald Trump signed an executive order Thursday to jumpstart the U.S. deep-sea mining industry. Trump seeks to secure domestic access to critical resources through this initiative and reduce America&#8217;s dependence on foreign supply chains for increasingly important commodities.</li>
<li>Shares of Baijiayun Group Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RTC#NASDAQ">RTC</a>)got a boost, surging 77% to $0.3288 as the company announced plans to invest tens of millions of dollars over next five years to establish new ecosystem for autism rehabilitation.</li>
<li>AGM Group Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGMH#NASDAQ">AGMH</a>) shares were also up, gaining 47% to $0.0572.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Azul S.A. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZUL#NYSE">AZUL</a>) shares dropped 45% to $0.6175.</li>
<li>Shares of Coeptis Therapeutics Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COEP#NASDAQ">COEP</a>) were down 33% to $8.35. Coeptis Therapeutics and Z Squared Inc. announced a merger agreement.</li>
<li>Lexaria Bioscience Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LEXX#NASDAQ">LEXX</a>) was down, falling 23% to $1.28 as the company announced a $2 million registered direct offering of common stock.</li>
</ul>
Commodities In commodity news, oil traded down 0.4% to $62.55 while gold traded down 1.7% at $3,293.10.
Silver traded down 2.1% to $32.805 on Friday, while copper fell 0.9% to $4.8120.
Euro zone
European shares were higher today. The eurozone's STOXX 600 gained 0.5%, Germany's DAX 40 gained 0.8% and France's CAC 40 gained 0.7%. Spain's IBEX 35 Index gained 1.3%, while London's FTSE 100 rose 0.2%.
Asia Pacific Markets
Asian markets closed mixed on Friday, with Japan's Nikkei 225 surging 1.90%, China's Shanghai Composite falling 0.07%, Hong Kong's Hang Seng Index gaining 0.32% and India's BSE Sensex falling 0.74%.
Economics
U.S. consumer confidence declined to 52.20 points in April compared to 57 points in March.
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/04/45006630/jim-cramer-onemain-is-too-risky-recommends-buying-reddit">Jim Cramer: OneMain Is &#8216;Too Risky,&#8217; Recommends Buying Reddit</a> </li>
</ul>
Read This Next:
<ul>
<li> <a href="https://www.benzinga.com/trading-ideas/long-ideas/25/04/45006630/jim-cramer-onemain-is-too-risky-recommends-buying-reddit">Jim Cramer: OneMain Is &#8216;Too Risky,&#8217; Recommends Buying Reddit</a> </li>
</ul>
Photo via Shutterstock

Earnings

Eurozone

Commodities

Intraday Update

AGMH

AZUL

COEP

GOOG

GOOGL

LEXX

OMEX

Dow Falls 200 Points; Alphabet Posts Upbeat Q1 Results

Needham analyst Gerald Pascarelli reiterates Boston Beer Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAM#NYSE">SAM</a>) from Hold to Hold.

Reiteration

Needham Reiterates Hold on Boston Beer Coto Hold

Citigroup analyst Ronald Josey maintains Wix.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WIX#NASDAQ">WIX</a>) with a Buy and lowers the price target from $280 to $238.

Citigroup Maintains Buy on Wix.com, Lowers Price Target to $238

Citigroup analyst Ygal Arounian maintains Wayfair (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/W#NYSE">W</a>) with a Neutral and raises the price target from $28 to $30.

Citigroup Maintains Neutral on Wayfair, Raises Price Target to $30

IONL

Trading Halt: Halt status updated at 10:06:28 AM ET: Quotation Resumption: News and Resumption Times

Seaport Global analyst Laurie Havener Hunsicker upgrades HarborOne Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HONE#NASDAQ">HONE</a>) from Neutral to Buy and announces $16 price target.

Upgrades

HONE

Seaport Global Upgrades HarborOne Bancorp to Buy, Announces $16 Price Target

Citigroup analyst Ygal Arounian maintains Trade Desk (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTD#NASDAQ">TTD</a>) with a Buy and lowers the price target from $70 to $63.

Citigroup Maintains Buy on Trade Desk, Lowers Price Target to $63

Citigroup analyst Ygal Arounian maintains Outbrain (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OB#NASDAQ">OB</a>) with a Neutral and lowers the price target from $5.9 to $4.

Citigroup Maintains Neutral on Outbrain, Lowers Price Target to $4

Revvity (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RVTY#NYSE">RVTY</a>) will release its quarterly earnings report on Monday, 2025-04-28. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate Revvity to report an earnings per share (EPS) of $0.96.
The announcement from Revvity is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.
It's worth noting for new investors that guidance can be a key determinant of stock price movements.
<h3>Performance in Previous Earnings</h3>
Last quarter the company beat EPS by $0.04, which was followed by a 0.0% drop in the share price the next day.
Here's a look at Revvity's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>1.38</td>
<td>1.13</td>
<td>1.12</td>
<td>0.93</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>1.42</td>
<td>1.28</td>
<td>1.22</td>
<td>0.98</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-1.0%</td>
<td>1.0%</td>
<td>1.0%</td>
<td>-2.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1745589817_0.png" alt="eps graph" />
<h3>Market Performance of Revvity's Stock</h3>
Shares of Revvity were trading at $95.13 as of April 24. Over the last 52-week period, shares are down 11.01%. Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release. 
<h3>Analysts' Perspectives on Revvity</h3>
For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Revvity.
The consensus rating for Revvity is Outperform, based on 6 analyst ratings. With an average one-year price target of $128.17, there's a potential 34.73% upside.
<h3>Peer Ratings Overview</h3>
In this analysis, we delve into the analyst ratings and average 1-year price targets of Avantor, Illumina and Tempus AI, three key industry players, offering insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Outperform trajectory for Avantor, with an average 1-year price target of $23.8, suggesting a potential 74.98% downside.</li>
<li>Analysts currently favor an Neutral trajectory for Illumina, with an average 1-year price target of $129.4, suggesting a potential 36.02% upside.</li>
<li>Analysts currently favor an Buy trajectory for Tempus AI, with an average 1-year price target of $63.78, suggesting a potential 32.95% downside.</li>
</ul>
<h3>Insights: Peer Analysis</h3>
The peer analysis summary presents essential metrics for Avantor, Illumina and Tempus AI, unveiling their respective standings within the industry and providing valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revvity</td>
<td>Outperform</td>
<td>4.81%</td>
<td>$412.29M</td>
<td>1.21%</td>
</tr>
<tr>
<td>Avantor</td>
<td>Outperform</td>
<td>-2.10%</td>
<td>$562.90M</td>
<td>8.70%</td>
</tr>
<tr>
<td>Illumina</td>
<td>Neutral</td>
<td>-1.60%</td>
<td>$728M</td>
<td>8.31%</td>
</tr>
<tr>
<td>Tempus AI</td>
<td>Buy</td>
<td>35.85%</td>
<td>$122.06M</td>
<td>-23.65%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Revvity ranks first in revenue growth among its peers. It has the lowest gross profit and return on equity compared to others.
<h3>Unveiling the Story Behind Revvity</h3>
Revvity provides instruments, tests, services, and software solutions to the pharmaceutical, biomedical, chemical, environmental, and general industrial markets. The company operates in two segments. First, its diagnostics segment includes immunodiagnostics, reproductive health, and applied genomics. Second, its discovery and analytical solutions is composed of life science, industrial, environmental, and food applications. Revvity offers products and services ranging from genetic screening and environmental analytical tools to informatics and enterprise software.
<h3>Understanding the Numbers: Revvity's Finances</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Revvity's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately 4.81%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 12.98%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Revvity's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 1.21%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 0.75%, the company showcases effective utilization of assets.
Debt Management: Revvity's debt-to-equity ratio is below the industry average. With a ratio of 0.43, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<a href="https://www.benzinga.com/quote/RVTY/earnings">To track all earnings releases for Revvity visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

RVTY

Earnings Preview For Revvity

Alexandria Real Estate (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARE#NYSE">ARE</a>) is gearing up to announce its quarterly earnings on Monday, 2025-04-28. Here's a quick overview of what investors should know before the release.
Analysts are estimating that Alexandria Real Estate will report an earnings per share (EPS) of $2.29.
Alexandria Real Estate bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Historical Earnings Performance</h3>
During the last quarter, the company reported an EPS missed by $0.00, leading to a 4.76% drop in the share price on the subsequent day.
Here's a look at Alexandria Real Estate's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>2.39</td>
<td>2.38</td>
<td>2.34</td>
<td>2.32</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>2.39</td>
<td>2.37</td>
<td>2.36</td>
<td>2.35</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-5.0%</td>
<td>-1.0%</td>
<td>-4.0%</td>
<td>1.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1745589800_0.png" alt="eps graph" />
<h3>Tracking Alexandria Real Estate's Stock Performance</h3>
Shares of Alexandria Real Estate were trading at $77.26 as of April 24. Over the last 52-week period, shares are down 35.93%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<h3>Analyst Insights on Alexandria Real Estate</h3>
For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Alexandria Real Estate.
A total of 2 analyst ratings have been received for Alexandria Real Estate, with the consensus rating being Neutral. The average one-year price target stands at $115.0, suggesting a potential 48.85% upside.
<h3>Comparing Ratings Among Industry Peers</h3>
In this comparison, we explore the analyst ratings and average 1-year price targets of Healthpeak Properties, Omega Healthcare Invts and Healthcare Realty Trust, three prominent industry players, offering insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Outperform trajectory for Healthpeak Properties, with an average 1-year price target of $23.75, suggesting a potential 69.26% downside.</li>
<li>Analysts currently favor an Neutral trajectory for Omega Healthcare Invts, with an average 1-year price target of $39.67, suggesting a potential 48.65% downside.</li>
<li>Analysts currently favor an Neutral trajectory for Healthcare Realty Trust, with an average 1-year price target of $16.5, suggesting a potential 78.64% downside.</li>
</ul>
<h3>Overview of Peer Analysis</h3>
Within the peer analysis summary, vital metrics for Healthpeak Properties, Omega Healthcare Invts and Healthcare Realty Trust are presented, shedding light on their respective standings within the industry and offering valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alexandria Real Estate</td>
<td>Neutral</td>
<td>2.78%</td>
<td>$522.82M</td>
<td>-0.36%</td>
</tr>
<tr>
<td>Healthpeak Properties</td>
<td>Outperform</td>
<td>26.07%</td>
<td>$420.96M</td>
<td>0.05%</td>
</tr>
<tr>
<td>Omega Healthcare Invts</td>
<td>Neutral</td>
<td>16.71%</td>
<td>$275.87M</td>
<td>2.59%</td>
</tr>
<tr>
<td>Healthcare Realty Trust</td>
<td>Neutral</td>
<td>-7.15%</td>
<td>$176.19M</td>
<td>-2.00%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Alexandria Real Estate ranks at the top for Revenue Growth and Gross Profit among its peers. However, it ranks at the bottom for Return on Equity. Overall, the company's performance is mixed compared to its peers, with strong revenue growth and gross profit but lower return on equity.
<h3>All You Need to Know About Alexandria Real Estate</h3>
Alexandria Real Estate Equities Inc is an urban office real estate investment trust (REIT). It is engaged in the business of providing space for lease to life science, agtech, and technology tenants. The company has established a market presence in key locations, including Greater Boston, the San Francisco Bay Area, New York City, San Diego, Seattle, Maryland, and Research Triangle, Texas, and Canada. The Company is a life science real estate investment trust focused on developing, redeveloping, and operating properties that provide space for lease to tenants in the life science industry.
<h3>Key Indicators: Alexandria Real Estate's Financial Health</h3>
Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.
Revenue Growth: Alexandria Real Estate's remarkable performance in 3 months is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 2.78%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Real Estate sector.
Net Margin: Alexandria Real Estate's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of -8.51%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Alexandria Real Estate's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -0.36%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Alexandria Real Estate's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -0.17%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Alexandria Real Estate's debt-to-equity ratio is below the industry average. With a ratio of 0.71, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<a href="https://www.benzinga.com/quote/ARE/earnings">To track all earnings releases for Alexandria Real Estate visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Glimpse of Alexandria Real Estate's Earnings Potential

Nucor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NUE#NYSE">NUE</a>) will release its quarterly earnings report on Monday, 2025-04-28. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate Nucor to report an earnings per share (EPS) of $0.56.
Anticipation surrounds Nucor's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Historical Earnings Performance</h3>
The company's EPS beat by $0.59 in the last quarter, leading to a 3.76% increase in the share price on the following day.
Here's a look at Nucor's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.63</td>
<td>1.47</td>
<td>2.35</td>
<td>3.65</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>1.22</td>
<td>1.49</td>
<td>2.68</td>
<td>3.46</td>
</tr>
<tr>
<td>Price Change %</td>
<td>4.0%</td>
<td>-6.0%</td>
<td>-1.0%</td>
<td>-9.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1745589789_0.png" alt="eps graph" />
<h3>Performance of Nucor Shares</h3>
Shares of Nucor were trading at $115.29 as of April 24. Over the last 52-week period, shares are down 33.91%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<h3>Analyst Views on Nucor</h3>
Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Nucor.
Analysts have given Nucor a total of 8 ratings, with the consensus rating being Outperform. The average one-year price target is $153.88, indicating a potential 33.47% upside.
<h3>Understanding Analyst Ratings Among Peers</h3>
This comparison focuses on the analyst ratings and average 1-year price targets of Steel Dynamics, Reliance and Carpenter Tech, three major players in the industry, shedding light on their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Neutral trajectory for Steel Dynamics, with an average 1-year price target of $145.0, suggesting a potential 25.77% upside.</li>
<li>Analysts currently favor an Outperform trajectory for Reliance, with an average 1-year price target of $327.0, suggesting a potential 183.63% upside.</li>
<li>Analysts currently favor an Outperform trajectory for Carpenter Tech, with an average 1-year price target of $237.5, suggesting a potential 106.0% upside.</li>
</ul>
<h3>Peers Comparative Analysis Summary</h3>
The peer analysis summary offers a detailed examination of key metrics for Steel Dynamics, Reliance and Carpenter Tech, providing valuable insights into their respective standings within the industry and their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nucor</td>
<td>Outperform</td>
<td>-8.17%</td>
<td>$626.83M</td>
<td>1.45%</td>
</tr>
<tr>
<td>Steel Dynamics</td>
<td>Neutral</td>
<td>12.84%</td>
<td>$441.73M</td>
<td>2.45%</td>
</tr>
<tr>
<td>Reliance</td>
<td>Outperform</td>
<td>11.45%</td>
<td>$886.10M</td>
<td>2.79%</td>
</tr>
<tr>
<td>Carpenter Tech</td>
<td>Outperform</td>
<td>8.44%</td>
<td>$177.50M</td>
<td>4.97%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Nucor ranks at the top for Gross Profit and Return on Equity among its peers. It is at the bottom for Revenue Growth.
<h3>About Nucor</h3>
Nucor Corp manufactures steel and steel products. The company's reportable segments are steel mills, steel products, and raw materials. A majority of its revenue is derived from the steel mills segment, which is engaged in producing sheet steel (hot-rolled, cold-rolled, and galvanized), plate steel, structural steel (wide-flange beams, beam blanks, H-piling, and sheet piling), and bar steel products. Nucor manufactures steel principally from scrap steel and scrap steel substitutes using electric arc furnaces (EAFs) along with continuous casting and automated rolling mills. The steel mills segment sells its products mainly to steel service centers, fabricators, and manufacturers located in the United States, Canada, and Mexico.
<h3>Nucor's Financial Performance</h3>
Market Capitalization Highlights: Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.
Revenue Growth: Nucor's revenue growth over a period of 3 months has faced challenges. As of 31 December, 2024, the company experienced a revenue decline of approximately -8.17%. This indicates a decrease in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Materials sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 4.16%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Nucor's ROE excels beyond industry benchmarks, reaching 1.45%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Nucor's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 0.86% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: With a below-average debt-to-equity ratio of 0.34, Nucor adopts a prudent financial strategy, indicating a balanced approach to debt management.
<a href="https://www.benzinga.com/quote/NUE/earnings">To track all earnings releases for Nucor visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Nucor's Earnings: A Preview

Shin-Etsu Chemical (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SHECY#OTC">SHECY</a>) is looking for Q1 GAAP EPS of $0.20. sees sales of $4.000 billion vs $664.80 billion analyst estimate.

Guidance

SHECY

Shin-Etsu Chemical Sees Q1 2026 GAAP Earning per ADS $0.20; Sees Sales $4.000B.

Press Releases

Tempus Announces Acquisition of Deep 6 AI

AI Influence on Medical Diagnostics Generating Billion Dollar Revenues While Growing Adoption Reduces Healthcare Costs

Tempus to Present at the 24th Annual Needham Virtual Healthcare Conference

Tempus Exhibits 4 Abstracts at the 2025 American College of Cardiology Annual Meeting

Illumina and Tempus partner to drive the future of precision medicine through genomic AI innovation

Global AI Diagnostics Market to Reach $8.54 Billion By 2033 as Industry Sees Increasing R&D and Strategic Collaborations

Tempus Unveils Advisory Board Featuring Leading Physicians From Across the U.S.

Tempus Signs Expanded Strategic Agreements with AstraZeneca and Pathos to Develop the Largest Multimodal Foundation Model in Oncology

Tempus to Report First Quarter 2025 Financial Results on May 6

Tempus Announces 18 Abstracts Accepted for Presentation at the American Association for Cancer Research Annual Meeting 2025

AVAI

BFRG

MDAI

TALK

TDOC

Agilent Technologies

AbCellera Biologics

Adaptive Biotechnologies Corporation - Common Stock

Adaptive Biotechnologies

Avantor

Azenta

Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories

BioLife Solutions

Bruker

Charles River Laboratories International, Inc. Common Stock

Charles River

Danaher

Evotec SE - American Depositary Shares each representing 1/2 of one ordinary share

Comments

Tempus AI

Interés en corto

Tempus AI (NASDAQ:TEM) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL